Background: Cardiovascular disease (CVD) is the lead cause of death around the world. Dyslipidemia is strongly associated with CVD. Magnesium (Mg) is an essential trace element involved in many vital biological process, such as glucose and lipid metabolism. Previous studies have showed that hypomagnesemia or Mg deficiency is associated with an increased risk of type 2 diabetes, metabolic syndrome, hypertension, and CVD. Objective: To explore the correlation between serum magnesium (Mg) concentration and dyslipidemia in health subjects and type 2 diabetes patients. Methods: 3430 health subjects were selected and divided into adult (aged 18~59) and elderly (≥60 years) groups according to age. In addition, 63 patients with type 2 diabetes were selected. Propensity score based on age, gender, body mass index (BMI) and smoking history was matched at a ratio of 1:2 between patients and health controls. Results: There was a significant correlation between elevated serum Mg concentration and dyslipidemia in health adults, but no significant correlation between the two in the health elderly. Multiple linear regression showed that serum total cholesterol (TC), BMI and smoking in men while fasting plasma glucose and serum LDL-C in women were independent risk factors for elevated serum Mg concentration. Whereas, no significant correlation was found between serum Mg concentration and lipid levels in T2DM patients. Conclusion: Serum Mg concentration is correlated with serum lipids to a certain extent, while age, gender and disease status may also exert certain confound effects. The causal relationship between serum Mg and dyslipidemia needs to be further studied.
| Published in | American Journal of Life Sciences (Volume 9, Issue 5) |
| DOI | 10.11648/j.ajls.20210905.15 |
| Page(s) | 134-140 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
Dyslipidemia, Serum Magnesium, Health Population, Type 2 Diabetes, Propensity Score Matching
| [1] | Alloubani A, Nimer R, Samara R. Relationship between hyperlipidemia, cardiovascular disease and stroke: a systematic review [J]. Curr Cardiol Rev. 2020. |
| [2] | Karr S. Epidemiology and management of hyperlipidemia [J]. Am J Manag Care. 2017, 23 (9 Suppl): S139-s48. |
| [3] | Fiorentini D, Cappadone C, Farruggia G, et al. Magnesium: biochemistry, nutrition, detection, and social impact of diseases linked to its deficiency [J]. Nutrients. 2021, 13 (4). |
| [4] | Severino P, Netti L, Mariani MV, et al. Prevention of cardiovascular disease: screening for magnesium deficiency [J]. Cardiol Res Pract. 2019, 2019: 4874921. |
| [5] | Guerrero-Romero F, Rodríguez-Morán M. Low serum magnesium levels and metabolic syndrome [J]. Acta Diabetol. 2002, 39 (4): 209-13. |
| [6] | Rusu M, Cristea V, Frenţiu T, et al. Magnesium and selenium in diabetics with peripheral artery disease of the lower limbs [J]. Clujul Med. 2013, 86 (3): 235-9. |
| [7] | Mitwalli AH. Why are serum magnesium levels lower in Saudi dialysis patients? [J] J Taibah Univ Med Sci. 2017, 12 (1): 41-6. |
| [8] | Nasri H, Baradaran A. Correlation of serum magnesium with dyslipidemia in maintenance hemodialysis patients [J]. Acta Medica 2004, 47 (4): 263-5. |
| [9] | Kauffman RP, Tullar PE, Nipp RD, et al. Serum magnesium concentrations and metabolic variables in polycystic ovary syndrome [J]. Acta Obstet Gynecol Scand. 2011, 90 (5): 452-8. |
| [10] | Workinger JL, Doyle RP, Bortz J. Challenges in the diagnosis of magnesium status [J]. Nutrients. 2018, 10 (9). |
| [11] | Ghasemi A, Zahediasl S, Syedmoradi L, et al. Low serum magnesium levels in elderly subjects with metabolic syndrome [J]. Biol Trace Elem Res. 2010, 136 (1): 18-25. |
| [12] | Guerrero-Romero F, Rodriguez-Moran M. Serum magnesium in the metabolically-obese normal-weight and healthy-obese subjects [J]. Eur J Intern Med. 2013, 24 (7): 639-43. |
| [13] | Srinivasan AR, Niranjan G, Kuzhandai Velu V, et al. Status of serum magnesium in type 2 diabetes mellitus with particular reference to serum triacylglycerol levels [J]. Diabetes Metab Syndr. 2012, 6 (4): 187-9. |
| [14] | Chavan VU, Ramavataram D, Patel PA, et al. Evaluation of serum magnesium, lipid profile and various biochemical parameters as risk factors of cardiovascular diseases in patients with rheumatoid arthritis [J]. J Clin Diagn Res. 2015, 9 (4): Bc01-5. |
| [15] | Mahalle N, Kulkarni MV, Naik SS. Is hypomagnesaemia a coronary risk factor among Indians with coronary artery disease? [J] J Cardiovasc Dis Res. 2012, 3 (4): 280-6. |
| [16] | Yamori Y, Sagara M, Mizushima S, et al. An inverse association between magnesium in 24-h urine and cardiovascular risk factors in middle-aged subjects in 50 CARDIAC Study populations [J]. Hypertens Res. 2015, 38 (3): 219-25. |
| [17] | Miturzyńska-Stryjecka H, Horubała-Bielak G, Markiewicz M. Concentration of magnesium and lipids in blood serum in a group of young healthy medical students [J]. Wiad Lek. 1993, 46 (3-4): 81-6. |
| [18] | Shalev H, Phillip M, Galil A, et al. Clinical presentation and outcome in primary familial hypomagnesaemia [J]. Arch Dis Child. 1998, 78 (2): 127-30. |
| [19] | Ansari MR, Maheshwari N, Shaikh MA, et al. Correlation of serum magnesium with dyslipidemia in patients on maintenance hemodialysis [J]. Saudi J Kidney Dis Transpl. 2012, 23 (1): 21-5. |
| [20] | Sharifi F, Mazloomi S, Hajihosseini R, et al. Serum magnesium concentrations in polycystic ovary syndrome and its association with insulin resistance [J]. Gynecol Endocrinol. 2012, 28 (1): 7-11. |
| [21] | Liu A, Xu P, Gong C, et al. High serum concentration of selenium, but not calcium, cobalt, copper, iron, and magnesium, increased the risk of both hyperglycemia and dyslipidemia in adults: A health examination center based cross-sectional study [J]. J Trace Elem Med Biol. 2020, 59: 126470. |
| [22] | Fischer M, Falkensammer C. New drug combination for medical management of hyperlipemia: clinical study [J]. Int J Clin Pharmacol Biopharm. 1977, 15 (12): 585-9. |
| [23] | Kisters K, Spieker C, Tepel M, et al. New data about the effects of oral physiological magnesium supplementation on several cardiovascular risk factors (lipids and blood pressure) [J]. Magnes Res. 1993, 6 (4): 355-60. |
| [24] | Schuitemaker GE, van der Pol GA, Aretz CP, et al. A placebo-controlled, double-blind, randomized trial of magnesium-pyridoxal-5'-phosphate-glutamate for hypercholesterolemia and other clinical-chemical risk factors of cardiovascular disease in a primary care setting [J]. Eur J Clin Pharmacol. 2001, 56 (12): 857-63. |
| [25] | Kirsten R, Heintz B, Nelson K, et al. Magnesium pyridoxal 5-phosphate glutamate reduces hyperlipidemia in patients with chronic renal insufficiency [J]. Eur J Clin Pharmacol. 1988, 34 (2): 133-7. |
| [26] | Petersen B, Christiansen C, Hansen PF. Treatment of hypercholesterolemia and hypertriglyceridemia with magnesium [J]. Acta Med Scand. 1976, 200 (1-2): 59-61. |
| [27] | Rashvand S, Mobasseri M, Tarighat-Esfanjani A. Effects of choline and magnesium concurrent supplementation on coagulation and lipid profile in patients with type 2 diabetes mellitus: a Pilot Clinical Trial [J]. Biol Trace Elem Res. 2020, 194 (2): 328-35. |
| [28] | Rademeyer LJ, Booyens J. The effects of variations in the fat and carbohydrate content of the diet on the levels of magnesium and cholesterol in the serum of white rats [J]. Br J Nutr. 1965, 19: 153-62. |
| [29] | Dai B, Li X, Xu J, et al. Synergistic effects of magnesium ions and simvastatin on attenuation of high-fat diet-induced bone loss [J]. Bioact Mater. 2021, 6 (8): 2511-22. |
| [30] | Kumar AR, Kurup PA. Membrane Na+ K+ ATPase inhibition related dyslipidemia and insulin resistance in neuropsychiatric disorders [J]. Indian J Physiol Pharmacol. 2001, 45 (3): 296-304. |
| [31] | Müller G, Pfordte K. Ultrafiltrable and protein-bound magnesium in serum of patients with hyperlipidaemia [J]. Clin Chim Acta. 1970, 30 (3): 583-6. |
| [32] | Evangelopoulos AA, Vallianou NG, Panagiotakos DB, et al. An inverse relationship between cumulating components of the metabolic syndrome and serum magnesium levels [J]. Nutrition Res. 2008, 28 (10): 659-63. |
| [33] | Sanya EO, Adeyanju OA, Olarinoye JK, et al. Magnesium supplementation did not affect the antiseizure property of ketogenic diet but reduced lipid dysmetabolism [J]. West Afr J Med. 2020, 37 (1): 7-12. |
| [34] | Sheu MJ, Chou PY, Lin WH, et al. Deep sea water modulates blood pressure and exhibits hypolipidemic effects via the AMPK-ACC pathway: an in vivo study [J]. Mar Drugs. 2013, 11 (6): 2183-202. |
APA Style
Han Tuo, Gong Hong, Mehreen Fatima, Li Ying, Fan Yajie, et al. (2021). Correlation Analysis of Serum Magnesium Concentration and Lipids in Health Population and Type 2 Diabetes Patients. American Journal of Life Sciences, 9(5), 134-140. https://doi.org/10.11648/j.ajls.20210905.15
ACS Style
Han Tuo; Gong Hong; Mehreen Fatima; Li Ying; Fan Yajie, et al. Correlation Analysis of Serum Magnesium Concentration and Lipids in Health Population and Type 2 Diabetes Patients. Am. J. Life Sci. 2021, 9(5), 134-140. doi: 10.11648/j.ajls.20210905.15
AMA Style
Han Tuo, Gong Hong, Mehreen Fatima, Li Ying, Fan Yajie, et al. Correlation Analysis of Serum Magnesium Concentration and Lipids in Health Population and Type 2 Diabetes Patients. Am J Life Sci. 2021;9(5):134-140. doi: 10.11648/j.ajls.20210905.15
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ajls.20210905.15,
author = {Han Tuo and Gong Hong and Mehreen Fatima and Li Ying and Fan Yajie and Song Wei and Yao Zhihui and Wang Qian and Wang Congxia},
title = {Correlation Analysis of Serum Magnesium Concentration and Lipids in Health Population and Type 2 Diabetes Patients},
journal = {American Journal of Life Sciences},
volume = {9},
number = {5},
pages = {134-140},
doi = {10.11648/j.ajls.20210905.15},
url = {https://doi.org/10.11648/j.ajls.20210905.15},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajls.20210905.15},
abstract = {Background: Cardiovascular disease (CVD) is the lead cause of death around the world. Dyslipidemia is strongly associated with CVD. Magnesium (Mg) is an essential trace element involved in many vital biological process, such as glucose and lipid metabolism. Previous studies have showed that hypomagnesemia or Mg deficiency is associated with an increased risk of type 2 diabetes, metabolic syndrome, hypertension, and CVD. Objective: To explore the correlation between serum magnesium (Mg) concentration and dyslipidemia in health subjects and type 2 diabetes patients. Methods: 3430 health subjects were selected and divided into adult (aged 18~59) and elderly (≥60 years) groups according to age. In addition, 63 patients with type 2 diabetes were selected. Propensity score based on age, gender, body mass index (BMI) and smoking history was matched at a ratio of 1:2 between patients and health controls. Results: There was a significant correlation between elevated serum Mg concentration and dyslipidemia in health adults, but no significant correlation between the two in the health elderly. Multiple linear regression showed that serum total cholesterol (TC), BMI and smoking in men while fasting plasma glucose and serum LDL-C in women were independent risk factors for elevated serum Mg concentration. Whereas, no significant correlation was found between serum Mg concentration and lipid levels in T2DM patients. Conclusion: Serum Mg concentration is correlated with serum lipids to a certain extent, while age, gender and disease status may also exert certain confound effects. The causal relationship between serum Mg and dyslipidemia needs to be further studied.},
year = {2021}
}
TY - JOUR T1 - Correlation Analysis of Serum Magnesium Concentration and Lipids in Health Population and Type 2 Diabetes Patients AU - Han Tuo AU - Gong Hong AU - Mehreen Fatima AU - Li Ying AU - Fan Yajie AU - Song Wei AU - Yao Zhihui AU - Wang Qian AU - Wang Congxia Y1 - 2021/11/05 PY - 2021 N1 - https://doi.org/10.11648/j.ajls.20210905.15 DO - 10.11648/j.ajls.20210905.15 T2 - American Journal of Life Sciences JF - American Journal of Life Sciences JO - American Journal of Life Sciences SP - 134 EP - 140 PB - Science Publishing Group SN - 2328-5737 UR - https://doi.org/10.11648/j.ajls.20210905.15 AB - Background: Cardiovascular disease (CVD) is the lead cause of death around the world. Dyslipidemia is strongly associated with CVD. Magnesium (Mg) is an essential trace element involved in many vital biological process, such as glucose and lipid metabolism. Previous studies have showed that hypomagnesemia or Mg deficiency is associated with an increased risk of type 2 diabetes, metabolic syndrome, hypertension, and CVD. Objective: To explore the correlation between serum magnesium (Mg) concentration and dyslipidemia in health subjects and type 2 diabetes patients. Methods: 3430 health subjects were selected and divided into adult (aged 18~59) and elderly (≥60 years) groups according to age. In addition, 63 patients with type 2 diabetes were selected. Propensity score based on age, gender, body mass index (BMI) and smoking history was matched at a ratio of 1:2 between patients and health controls. Results: There was a significant correlation between elevated serum Mg concentration and dyslipidemia in health adults, but no significant correlation between the two in the health elderly. Multiple linear regression showed that serum total cholesterol (TC), BMI and smoking in men while fasting plasma glucose and serum LDL-C in women were independent risk factors for elevated serum Mg concentration. Whereas, no significant correlation was found between serum Mg concentration and lipid levels in T2DM patients. Conclusion: Serum Mg concentration is correlated with serum lipids to a certain extent, while age, gender and disease status may also exert certain confound effects. The causal relationship between serum Mg and dyslipidemia needs to be further studied. VL - 9 IS - 5 ER -
Email: